B. Riley Wealth Advisors 13F: Adds $3.2M to LLY Stake

B. Riley Wealth Advisors Expands Position

B. Riley Wealth Advisors increased its holdings in Eli Lilly and Company NYSE:LLY during the recent period, according to a Form 13F filing with the Securities and Exchange Commission. The advisory firm added 2,742 shares to its portfolio, representing a 12.3% increase from the prior quarter. That brought its total ownership to 25,044 shares. At the close of the reporting window, the investment was valued at approximately $28.98 million. Institutional filings reflect portfolio holdings as of a specific date and may not capture current trading activity.

Eli Lilly and Company Stock Performance

Shares of the drug maker trade within a 52-week band ranging from a low of $783.85 to a peak of $1,292.65. The equity currently changes hands well above its 200-day moving average of $1,079.02. The company commands a market capitalization well into the billions, supported by strong demand for its pharmaceutical treatments.

Recent Analyst Updates

Wall Street research firms have adjusted their views on the stock through recent weeks. On October 12, 2026, RBC Capital reiterated an outperform rating alongside a price target of $1,500.00. Cantor Fitzgerald maintained an overweight stance on October 8, 2026, while moving its target to $1,440.00. Morgan Stanley kept an overweight rating on October 7, 2026, with a target of $1,430.00. Earlier, JP Morgan maintained an overweight rating on September 28, 2026, adjusting its target to $1,500.00. TD Cowen reiterated a buy rating at $1,250.00 on September 22, 2026, and Guggenheim kept a buy rating with a target of $1,284.00 on September 18, 2026. HSBC maintained a reduce rating and set a target of $940.00 on September 10, 2026, while Truist Securities held a buy rating at a $1,376.00 target on August 7, 2026.

Overview of Operations

Eli Lilly and Company discovers, develops, and delivers pharmaceutical therapies worldwide. Its product portfolio spans treatments for cardiometabolic conditions, oncology care, immunology, and neurological disorders. The organization serves patients and healthcare providers globally from its headquarters in Indianapolis, Indiana.

What to Watch at Eli Lilly and Company

Investors are looking ahead to the company's upcoming earnings report scheduled for October 29, 2026, which will provide fresh data on quarterly financial results. Future regulatory filings will also show whether advisory firms like B. Riley adjust their positions further as market conditions evolve.